ライフサイエンスコーパス: live @3 vaccine

1 is a plausible correlate of attenuation for live viral vaccines.

2 vaccines and most other strategies involving live virus vaccines.

3 ing immunization of a 78-year-old woman with live zoster vaccine.

4 ping a safe and potentially more efficacious live attenuated vaccine.

5 l tropism of a virus is a new approach for a live attenuated vaccine.

6 th -19% (95% CI, -113 to 33; P=0.55) for the live attenuated vaccine.

7 culated for the inactivated vaccines and the live attenuated vaccine.

8 n vivo and supports targeting the SH gene in live attenuated vaccines.

9 ations are good candidates for the design of live attenuated vaccines.

10 ored ILTV vaccines are less efficacious than live attenuated vaccines.

11 onally attenuate hMPV for the development of live attenuated vaccines.

12 man paramyxoviruses for rationally designing live attenuated vaccines.

13 gy, which combines the advantages of DNA and live attenuated vaccines.

14 s that can be mutated to generate successful live attenuated vaccines.

15 o understand virus biology and develop novel live attenuated vaccines.

16 option as safe, immunogenic, and protective live-attenuated vaccines.

17 cell culture has hindered the development of live-attenuated vaccines.

18 ty and activity is a strategy for generating live-attenuated vaccines.

19 ize may be more informative on the safety of live-attenuated vaccines.

20 ortant determinants of the immunogenicity of live-virus oral vaccines.

21 l adjuvants and licensed vaccines, including live attenuated BCG vaccine.

22 should improve the safety and efficacy of a live attenuated RSV vaccine.

23 athology is a key correlate of the safety of live mycobacterial vaccines.

24 because of the potential to generate better live attenuated NDV vaccines.

25 value of including such a mutation in future live attenuated RSV vaccines.

26 eviously exposed to DENV4 infections or to a live attenuated DENV4 vaccine.

27 mune responses following nasal delivery of a live attenuated viral vaccine.

28 d may translate into improved manufacture of live-attenuated hRSV vaccines.

29 lenge model to better evaluate the candidate live attenuated dengue vaccines.

30 une responses elicited by vaccination with a live attenuated type II vaccine.

31 rovirus-like particle vaccines but also as a live-attenuated vectored vaccine.

32 H2N2), the backbone of the licensed seasonal live attenuated influenza vaccine.

33 ich is the backbone of the licensed seasonal live attenuated influenza vaccine.

34 have emerged about the effectiveness of the live attenuated influenza vaccine.

35 oing testing, including genetically modified live-attenuated parasite vaccines.

36 safe and effective platform for creation of live attenuated RNA viral vaccines.

37 he rational development of other efficacious live attenuated flavivirus vaccines.

38 development of safe, stable, and protective live-attenuated arenavirus vaccines.

39 ased approach as a novel strategy to develop live-attenuated arenavirus vaccines.

40 vaccine as well as further reduce costs for live-attenuated oral polio vaccines.

41 ccine, but not to adjuvanted vaccines or the live-attenuated yellow fever vaccine.

42 cell-inducing vaccines, including vectored, live attenuated, and subunit vaccines.

43 enic influenza virus and immunization with a live attenuated influenza virus vaccine.

44 hallenge the level of protection provided by live attenuated oral rotavirus vaccines.

45 ter randomized controlled trial [cRCT]) used live attenuated influenza vaccine, 11 (7 cRCTs) used ina

46 We propose that this live attenuated vaccine acts like a silent natural infec

47 d and the polymerase could be used to design live attenuated vaccines against serious pathogens withi

48 To explore the potential of a live rAd vaccine against malaria, we prepared a viable a

49 ications for development of both subunit and live-attenuated vaccines against ETEC and other enteric

50 A similar approach may guide the design of live-attenuated vaccines against Lassa and other arenavi

51 However, live attenuated vaccines also induce strong CD8 T cell r

52 88(-/-) and Card9(-/-) mice immunized with a live, attenuated vaccine also fail to acquire protective

53 VE did not appear to be different for live-attenuated and inactivated vaccines among children

54 4 T cell responses elicited by a tetravalent live attenuated dengue vaccine and show that they resemb

55 confirmed in 210 (18%) of 1173 recipients of live attenuated influenza vaccine and 105 (18%) of place

56 dren were randomly assigned, 1174 to receive live attenuated influenza vaccine and 587 to receive pla

57 or the observed reduced effectiveness of the live attenuated influenza vaccine and highlight the unde

58 ht is critical for future rational design of live virus vaccines and their safety evaluation; attenua

59 d, these macaques were boosted i.m. with the live-attenuated trachoma vaccine and their peripheral T

60 r quality control of new lots of the current live-attenuated vaccine and provide insight for the rati

61 applied to current commercial PRRSV modified live-virus (MLV) vaccines and other candidate vaccines.

62 rts superseded by a final report, studies of live-attenuated vaccine, and studies of prepandemic seas

63 mmune responses similar to those elicited by live-attenuated vaccines, and its flexibility permits th

64 Live attenuated vaccines appear to be the most effective

65 The live attenuated influenza vaccine appears to protect par

66 Experimental live attenuated RSV vaccines are grown in Vero cells, bu

67 Novel live attenuated vaccines are being developed that promis

68 Live attenuated vaccines are commonly used in the poultr

69 Live attenuated vaccines are considered the most viable

70 Live attenuated vaccines are more immunogenic and have t

71 Although live fungal vaccines are efficient in driving protective

72 ger studies of intradermal administration of live, attenuated zoster vaccine are needed to provide co

73 Two doses of live-attenuated varicella-zoster vaccine are recommended

74 ults suggest that EHV-1 KyA may be used as a live attenuated EHV-1 vaccine as well as a prophylactic

75 ion may serve as a novel approach to develop live attenuated vaccines as well as antiviral drugs for

76 tivity can lead to the development of novel, live attenuated vaccines, as well as antiviral drugs for

77 ong children whose last vaccine received was live compared with inactivated vaccine, as well as concu

78 l vaccines are typically not as efficient as live attenuated or inactivated vaccines at inducing prot

79 Eligible patients received live zoster vaccine at investigators' discretion.

80 al, we assessed the efficacy and safety of a live attenuated influenza vaccine based on Russian-deriv

81 consideration should be taken when designing live attenuated vaccines based on deletions of nonstruct

82 new avenue for the development of arenavirus live attenuated vaccines based on rearrangement of their

83 se findings provide a pathway for developing live attenuated virus vaccines based on engineering the

84 n children who received minimally attenuated live RSV vaccines but not in children who received highl

85 y exposed to DENV and was immunized with the live attenuated tetravalent vaccine Butantan-DV, develop

86 /1/1981 (eq/GA/81) was selected to produce a live attenuated candidate vaccine by reverse genetics wi

87 The present uncertainty of which live viral or bacterial vaccines can be given to immunod

88 excellent safety profile and high stability, live-attenuated CDV vaccines can retain residual virulen

89 Therefore, we generated a live attenuated avian H3N8 vaccine candidate and demonst

90 We generated a live attenuated H3N8 vaccine candidate and demonstrated

91 test the protective potential of the novel, live attenuated pertussis vaccine candidate BPZE1.

92 Here, we analyze immunity induced by a live tuberculosis vaccine candidate, recombinant BCG Del

93 Collectively, we developed an improved live vectored vaccine candidate for human NoV which will

94 DeltamsbB double mutant could provide a new live-attenuated background vaccine candidate strain, and

95 letion (DeltaNS2) to produce the recombinant live-attenuated RSV vaccine candidate DeltaNS2/Delta1313

96 Here we report on a live-attenuated vaccine candidate that contains a 10-nuc

97 that further development of this promising, live-attenuated ZIKV vaccine candidate is warranted.

98 We designed new live attenuated RSV vaccine candidates by codon-pair deo

99 rational development of safe and protective live attenuated vaccine candidates based on genome reorg

100 ps but also will lead to the development new live attenuated vaccine candidates for hMPV.

101 can be assembled and have been developed as live attenuated vaccine candidates for several flaviviru

102 h potential for further development as novel live attenuated vaccine candidates that may rapidly cont

103 to safely attenuate FMDV and further develop live attenuated vaccine candidates to control such a fea

104 could form the basis of a new generation of live attenuated vaccine candidates.

105 nymous but suboptimal substitutions provides live attenuated vaccine candidates.

106 herefore, ensure the environmental safety of live tick-borne virus vaccine candidates.

107 Analysis of sera from recipients of live-attenuated monovalent DENV vaccine candidates revea

108 bility of a CD-based approach for developing live-attenuated vaccine candidates against human-pathoge

109 We therefore generated 2 live-attenuated vaccine candidates based on the insertio

110 Here we demonstrate that live-attenuated Zika virus vaccine candidates containing

111 or the rational design of second-generation, live-attenuated, recombinant JEV vaccine candidates.

112 We have generated a live attenuated viral (LAV) vaccine capable of eliciting

113 Vaccination with the live attenuated influenza vaccine causes a localized acu

114 The current live attenuated vaccines (chicken embryo origin [CEO] an

115 ved at least 1 dose of either inactivated or live attenuated influenza vaccine compared with 0.8%-4.3

116 91, respectively) and for those who received live and inactivated vaccines concurrently compared with

117 have improved the safety of a mouse-adapted live attenuated influenza vaccine containing the same at

118 to receive three injections of recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) o

119 o receive three injections of a recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV),

120 as developed a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) th

121 ve previously shown that a plasmid-deficient live-attenuated trachoma vaccine delivered ocularly to m

122 demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the firs

123 People exposed to serotype 4 infections or a live attenuated serotype 4 vaccine developed neutralizin

124 versus lower respiratory tract and bear upon live attenuated vaccine development.

125 Two girls who had received live attenuated influenza vaccine died, one due to anasa

126 ach to the development of safe and effective live attenuated vaccines directed against VEEV and other

127 ach to the development of safe and effective live attenuated vaccines directed against VEEV and perha

128 ants receiving the monovalent or tetravalent live attenuated DENV vaccine (DLAV), developed by the U.

129 We show that a live-attenuated HSV-1 vaccine elicits humoral immune res

130 id a combination of a commercially available live fowl poxvirus vaccine expressing the H5 influenza v

131 The live attenuated influenza vaccine FluMist has been prove

132 rtance of the production capabilities of the live attenuated influenza vaccine for pandemic preparedn

133 ade an interim recommendation not to use the live attenuated influenza vaccine for the 2016-2017 infl

134 We generated 2 influenza A(H5N1) live attenuated influenza vaccines for pandemic use (pLA

135 Development of a live attenuated vaccine for human NoV has not been possi

136 serve as a novel target to rationally design live attenuated vaccines for aMPV and perhaps other para

137 rstanding may also enable the development of live attenuated vaccines for both RSV and other members

138 for the development of safe and efficacious live attenuated vaccines for hMPV and other human paramy

139 serve as a novel target to rationally design live attenuated vaccines for hMPV and perhaps other para

140 aches would add an HPV component to existing live attenuated vaccines for measles and typhoid fever.

141 s but also facilitate the development of new live attenuated vaccines for VSV, and perhaps other NNS

142 amed BPZE1, is being developed as a possible live nasal vaccine for the prevention of whooping cough.

143 ation highlights the potential need to defer live virus vaccines for at least 6 months in exposed neo

144 r (HZ) vaccines may be an alternative to the live-attenuated HZ vaccine for immunocompromised individ

145 A live-attenuated vaccine for RVF, the MP-12 vaccine, is c

146 ovided an opportunity to design a successful live-attenuated vaccine for SARS-CoV and opens avenues f

147 novel approach to produce safe and effective live-attenuated vaccines for DENV and other insect-borne

148 The live attenuated zoster vaccine generates immune response

149 These findings put forward a promising live attenuated influenza vaccine generation strategy to

150 Here, we demonstrate that a live-attenuated HSV-1 vaccine has great translational po

151 Live attenuated influenza vaccines have been shown to si

152 The live oral rotavirus (RV) vaccines have shown a reduced e

153 Live oral rotavirus (RV) vaccines have shown modest effi

154 Although live-attenuated vaccines have been safely administered t

155 ompared with inactivated alone or concurrent live and inactivated vaccines (HR, 0.50; 95% confidence

156 Live attenuated herpes zoster vaccine (HZV) reduces that

157 IAV) that are safe and effective as modified live attenuated (att) virus vaccines (IAV att).

158 Taken together, our data indicate that a live attenuated HSV-2 vaccine impaired for infection of

159 n could improve the safety and efficacy of a live attenuated RSV vaccine.IMPORTANCE RSV binds to the

160 Live attenuated influenza vaccines in the United States

161 f protection conferred by a highly effective live attenuated SIV vaccine in the rhesus macaque animal

162 RSV DeltaSH has been tested as a live attenuated vaccine in humans and cattle, and here w

163 eficient Chlamydia trachomatis to serve as a live attenuated vaccine in the genital tract.

164 assess the dynamics of genetic reversion of live poliovirus vaccine in humans, we studied molecular

165 nitiated a pilot introduction of the Rotarix live, oral rotavirus vaccine in all public health facili

166 n eggs and has the potential to be used as a live-attenuated vaccine in humans.

167 Because concerns exist about the use of live-attenuated vaccines in immunocompromised individual

168 (ii) How long-lived are these vaccine-induced stalk-reactive antibody

169 1 envelope (Env) antigens (Ag) for more long-lived, efficacious HIV-1 vaccine-induced B-cell response

170 V biology, including human host-pathogen and live, attenuated vaccine interactions; host and cell typ

171 The first dose of live attenuated measles-containing vaccines is associate

172 A live attenuated vaccine is the most promising vaccine st

173 Live attenuated varicella vaccine is recommended for hea

174 Efficacy of live oral rotavirus vaccines is reduced in low-income co

175 vaccines.IMPORTANCE The genetic stability of live viral vaccines is important for safety and efficacy

176 The live-attenuated Candid#1 vaccine is used in Argentina to

177 tant to prevent the spread of disease, and a live-attenuated MP-12 vaccine is currently the only vacc

178 A live-attenuated MP-12 vaccine is one of the best-charact

179 Rs.IMPORTANCE A chimeric yellow fever-dengue live-attenuated tetravalent vaccine is now being markete

180 rse genetics techniques, we have developed a live-attenuated CIV vaccine (LACIV) for the prevention o

181 za virus infection in humans, we developed a live attenuated H7N9 influenza vaccine (LAIV) with two a

182 e safety and immunogenicity of an avian H5N2 live attenuated influenza vaccine (LAIV H5N2) in healthy

183 Live attenuated influenza vaccine (LAIV) and inactivated

184 the 2 currently licensed influenza vaccines, live attenuated influenza vaccine (LAIV) and inactivated

185 Live attenuated influenza vaccine (LAIV) and trivalent i

186 al efficacy and safety of a Russian-backbone live attenuated influenza vaccine (LAIV) at two field si

187 Therefore, this H7N9 live attenuated influenza vaccine (LAIV) candidate has b

188 omized, placebo-controlled clinical trial of live attenuated influenza vaccine (LAIV) in children age

189 Live attenuated influenza vaccine (LAIV) is an intranasa

190 Whether vaccinating children with intranasal live attenuated influenza vaccine (LAIV) is more effecti

191 The live attenuated influenza vaccine (LAIV) is preferential

192 The live attenuated influenza vaccine (LAIV) is the preferre

193 on Practices recommended preferential use of live attenuated influenza vaccine (LAIV) over inactivate

194 onses in tonsils and saliva after intranasal live attenuated influenza vaccine (LAIV) vaccination in

195 s of inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV) were tested by

196 The live attenuated influenza virus vaccine (LAIV) is prefer

197 tivated influenza vaccine (TIV) or trivalent live-attenuated influenza vaccine (LAIV) in Thailand.

198 ent 2009 pandemic influenza A(H1N1) virus or live-attenuated influenza vaccine (LAIV) or who had labo

199 l of inactivated influenza vaccine (IIV) and live-attenuated influenza vaccine (LAIV) performed durin

200 mbinant, temperature-sensitive H3N8 CIV as a live-attenuated influenza vaccine (LAIV), which was atte

201 limited immune responses and, in the case of live-attenuated influenza virus vaccines (LAIV), there a

202 months and the effectiveness of quadrivalent live attenuated influenza vaccine (LAIV4) among children

203 Recent studies have shown that live attenuated influenza vaccines (LAIVs) expressing av

204 However, recent formulations of live attenuated influenza vaccines (LAIVs) have not been

205 Live attenuated influenza vaccines (LAIVs) on temperatur

206 Live attenuated influenza vaccines (LAIVs) stimulate a m

207 Live-attenuated influenza vaccines (LAIVs) have the pote

208 pproach to generate safer and more efficient live-attenuated influenza virus vaccines (LAIVs) based o

209 completion, and the chances that one or more live attenuated tetravalent vaccines (LATVs) will be int

210 /LASV reassortant (ML29) is a LASV candidate live-attenuated vaccine (LAV) that has shown promising r

211 ain Edmonston-Zagreb has long been used as a live-attenuated vaccine (LAV) to protect against measles

212 Implementation of live-attenuated vaccines (LAV) will represent a major st

213 Vaccination with live attenuated vaccines (LAVs) is an effective way for

214 Live-attenuated vaccines (LAVs) are the most advanced va

215 RSV live-attenuated vaccines (LAVs) have a history of safe t

216 Implementation of live-attenuated vaccines (LAVs) will represent a major s

217 These results suggest that the success of live dengue vaccines may depend on their ability to stim

218 Thus, a live vector-based vaccine may provide an alternative vac

219 lls play an important but unexpected role in live-attenuated trachoma vaccine-mediated protective imm

220 Healthy volunteers received either live attenuated BCG vaccine (n = 20) or placebo (n = 20)

221 of illness, and reactogenicity of candidate live dengue virus vaccines of uncertain attenuation.

222 To secure a polio-free world, the live attenuated oral poliovirus vaccine (OPV) will event

223 forts include high vaccination coverage with live oral polio vaccine (OPV), surveillance for acute fl

224 Response to challenge with live, attenuated, oral polio vaccine (OPV) is a measure

225 er polio eradication is achieved, the use of live-attenuated oral poliovirus vaccine (OPV) must be di

226 cations containing mouse protection data for live attenuated Brucella vaccines or vaccine candidates.

227 a single intranasal dose of masked trivalent live attenuated influenza vaccine or placebo.

228 ess and safety concerns regarding the use of live attenuated vaccines or potent adjuvants in this pop

229 ated a candidate A/Anhui/2013(H7N9) pandemic live attenuated influenza vaccine (pLAIV) in healthy adu

230 We investigated the HA stability of pandemic live attenuated influenza vaccine (pLAIV) viruses and ob

231 valuation of pairs of wild-type and pandemic live attenuated influenza virus vaccines (pLAIV) represe

232 We have developed pandemic live attenuated influenza vaccines (pLAIVs) against clad

233 We generated seven reassortant pandemic live attenuated influenza vaccines (pLAIVs) with the hem

234 A live-attenuated malaria vaccine, Plasmodium falciparum s

235 us, opening the possibility for its use as a live-attenuated vaccine platform for ZIKV and other clin

236 As modified mRNA and live-attenuated vaccine platforms can restrict in utero

237 s a novel technology to sufficiently deliver live attenuated vaccine powders into the skin.

238 ls spanning the past 28 years, opposition to live-attenuated HSV vaccines predicated on unfounded saf

239 Live-attenuated vaccines present safety challenges, and

240 ere Shan et al. show that a single dose of a live-attenuated Zika vaccine prevents infection, testis

241 In 2013 England and Wales began to fund a live attenuated influenza vaccine programme for individu

242 ummary, our data indicate that attenuated or live viral vaccines promote cytokine-induced memory-like

243 bo-controlled trial of inactivated (IIV) and live-attenuated (LAIV) influenza vaccines provided blood

244 In low-income countries, live measles vaccine reduces mortality from causes other

245 The development of live viral vaccines relies on empirically derived phenot

246 CD8(+) T cell responses elicited by a dengue live attenuated virus (DLAV) vaccine resemble those obse

247 Immunization of mice with live RABV-based vaccines results in accumulation of macr

248 While RABV vaccines are inactivated, the live-attenuated CDV vaccines retain residual virulence f

249 ially be further tested and developed into a live attenuated plague vaccine(s).

250 This case illustrates a circumstance when a live viral vaccine should not be used.

251 While live mycobacterial vaccines show promising efficacy, HIV

252 Finally, using the mutant as a live-attenuated vaccine showed significant promise for p

253 We demonstrate that a live attenuated influenza vaccine significantly reduces

254 This has implications for the design of live attenuated HPIV3 vaccines; specifically, the antibo

255 The first comparison of a live RNA viral vaccine strain to its wild-type parental

256 The live, attenuated varicella vaccine strain (vOka) is the

257 d-generation Candid#1 vaccine.IMPORTANCE The live-attenuated Candid#1 vaccine strain of Junin virus i

258 generated a reverse genetics system for the live-attenuated MV vaccine strain Edmonston-Zagreb (EZ),

259 th protection against plague, we developed a live-attenuated vaccine strain by deleting the Braun lip

260 tibility of the glycoprotein of the Candid#1 live-attenuated vaccine strain of JUNV in MACV replicati

261 A number of live attenuated RSV vaccine strains have been developed

262 , we developed nonreverting, nonreplicating, live attenuated uracil auxotroph vaccine strains in the

263 Live attenuated vaccine strains, such as type I nonrepli

264 coding engineered polymerases might serve as live, attenuated vaccine strains.

265 ge could be harnessed for the development of live-attenuated vaccine strains to combat HFAs.

266 lian host and warrant further development as live-attenuated vaccine strains.

267 Studies with live attenuated Leishmania vaccines such as centrin dele

268 Live attenuated vaccines such as SIV with a deleted nef

269 viral infection or as an adverse reaction to live-virus vaccines such as measles, mumps and rubella (

270 Decades of success with live adenovirus vaccines suggest that replication-compet

271 Ten subjects previously vaccinated with a live attenuated tetravalent dengue vaccine (TDV) and 4 D

272 We are developing a live-attenuated tetravalent dengue vaccine (TDV) candida

273 sults of vaccinating mice with a new type of live attenuated HSV-2 vaccine that is impaired for infec

274 that might be deleted for the development of live attenuated vaccines that would be safer to use in s

275 enetic engineering now enables the design of live viral vaccines that are potentially transmissible.

276 ica serovar Enteritidis DeltaguaBA DeltaclpX live oral vaccines to protect mice against a highly leth

277 etermine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to indu

278 monstrate the safety and immunogenicity of a live attenuated tetravalent dengue vaccine (TV003), comp

279 Live-attenuated vaccines typically offer rapid and durab

280 In this report, we show that live RABV-based vaccine vectors efficiently infect naive

281 o preserve the transcriptional competence of live recombinant viral vaccine vectors in the absence of

282 Live attenuated H7N9 influenza vaccine viruses that poss

283 ic attenuation and host-range restriction of live attenuated vaccine viruses.

284 The A(H1N1)pdm09 virus strain used in the live attenuated influenza vaccine was changed for the 20

285 Live attenuated influenza vaccine was well tolerated in

286 However, the live attenuated vaccine was found to be ineffective amon

287 fective (95% CI, 47 to 70; P<0.001), and the live attenuated vaccine was not observed to be effective

288 t the stalk and catalytic domains of NA as a live attenuated vaccine was shown to confer a strong IAV

289 he 2016-2017 A(H1N1)pdm09 strain used in the live attenuated vaccine was unchanged from 2015-2016, th

290 The live-attenuated vaccine was used to assess the impact of

291 a VLP, whole inactivated influenza virus, or live attenuated influenza virus vaccines were not protec

292 ruses and human infections, new candidate H5 live attenuated vaccines were developed by using two dif

293 Two live oral rotavirus vaccines were approved by the US Foo

294 rinary RVF vaccine in the United States is a live-attenuated MP-12 vaccine, which is conditionally li

295 ical disease similar to that provided by the live attenuated commercial vaccines, with no decrease in

296 means to increase the antibody response to a live attenuated HPIV3 vaccine without affecting viral re

297 5 million deaths per year: Every minute five lives are saved by vaccines worldwide.

298 cohort of 80 individuals immunized with the live attenuated yellow fever vaccine (YFV-17D) by sampli

299 hy young and older adults immunized with the live attenuated shingles vaccine Zostavax.

300 on against herpes zoster (HZ) induced by the live attenuated zoster vaccine Zostavax (ZVL) wanes with